Skip to main content

Table 3 Baseline demographic and clinical features of RA and OA patients in the study of PGC-1β expression in FLS by qPCR and western blot

From: Down-regulating peroxisome proliferator-activated receptor-gamma coactivator-1beta alleviates the proinflammatory effect of rheumatoid arthritis fibroblast-like synoviocytes through inhibiting extracellular signal-regulated kinase, p38 and nuclear factor-kappaB activation

Characteristic RA patients (n = 8) OA patients (n = 6)
Demographic   
Age, yrs, median (range) 55 (33 to 70) 57 (51 to 68)
Female, n (%) 8 (100) 6 (100)
Disease status   
Disease duration, mo, median (range) 78 (2 to 240) 36 (12 to 168)
ESR, mm/h, median (range) 50 (11 to 83) 18 (12 to 32)
CRP, mg/dl, median (range) 1.53 (0.02 to 4.55) 0.33 (0.08 to 1.11)
Rheumatoid factor-positive, n (%) 7 (87.5) NA
Anti-CCP-positive, n (%) 8 (100) NA
DAS28, median (range) 4.36 (3.06 to 5.82) NA
Previous medications, n (%)   NA
Corticosteroids 3 (37.5) NA
Methotrexate 4 (50) NA
Leflunomide 3 (37.5) NA
Hydroxychloroquine 2 (25) NA
Infliximab 1 (12.5) NA
Etanercept 1 (12.5) NA
  1. FLS, fibrolast-like synoviocytes; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score 28-joint assessment; n, number of patients; RA, rheumatoid arthritis; OA, osteoarthritis; NA, not applicable.